Indoco Remedies Limited (NSE:INDOCO)
India
· Delayed Price · Currency is INR | Market Cap | 19.52B |
| Revenue (ttm) | 17.60B |
| Net Income (ttm) | -1.14B |
| Shares Out | 92.30M |
| EPS (ttm) | -11.75 |
| PE Ratio | n/a |
| Forward PE | 72.76 |
| Dividend | 0.20 (0.09%) |
| Ex-Dividend Date | Sep 4, 2025 |
| Volume | 23,352 |
| Average Volume | 50,501 |
| Open | 214.80 |
| Previous Close | 211.45 |
| Day's Range | 207.32 - 214.80 |
| 52-Week Range | 162.19 - 349.80 |
| Beta | 0.44 |
| RSI | 56.84 |
| Earnings Date | May 13, 2026 |
About Indoco Remedies
Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibioti... [Read more]
Financial Performance
Financial StatementsNews
Pharma sector stocks surge today, April 15: Indoco Remedies up 5%, Orchid Pharma gains 4.04%, Dr. Reddy's falls 1.64%
Indian pharmaceutical sector stocks traded higher in early morning trade on Tuesday, April 15, 2026, with most counters advancing while Dr. Reddy's Laboratories remained an outlier on the downside. Am...
Indoco Remedies receives USFDA final approval for Brivaracetam Oral Solution 10 mg/mL
Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug...
Q3 2026 Indoco Remedies Ltd Earnings Call Transcript
Q3 2026 Indoco Remedies Ltd Earnings Call Transcript
Indoco Remedies Transcript: Q3 25/26
Q3 FY26 saw strong export and API growth, improved subsidiary performance, and higher gross margins. Europe and OTC businesses are set for robust growth, while one-time costs from regulatory issues impacted results. Debt reduction and margin improvement remain key priorities.
Indoco Remedies Q3 Results: Revenue rises 8.5% YoY to Rs 445.4 crore, net loss at Rs 29.8 crore
Indoco Remedies reported its Q3 financial results, showing steady growth in revenue and operating profitability on a year-on-year basis, while...
Indoco Remedies Ltd (BOM:532612) Q2 2026 Earnings Call Highlights: Revenue Growth and Strategic ...
Indoco Remedies Ltd (BOM:532612) Q2 2026 Earnings Call Highlights: Revenue Growth and Strategic Challenges
Q2 2026 Indoco Remedies Ltd Earnings Call Transcript
Q2 2026 Indoco Remedies Ltd Earnings Call Transcript
Indoco Remedies Transcript: Q2 25/26
Q2 FY26 saw strong revenue growth and margin recovery, driven by robust India and emerging market performance, new product launches, and operational improvements. USFDA remediation and subsidiary losses remain key risks, but management expects further growth, margin expansion, and limited CapEx ahead.
Indoco Remedies’ Patalganga API facility clears USFDA inspection with zero observations
Indoco Remedies Limited, a leading Indian pharmaceutical company, announced today that its Active Pharmaceutical Ingredients (API) manufacturing facility at Patalganga, Navi Mumbai, has successfully p...
Why are Indoco Remedies shares up 2% today? Explained
Indoco Remedies Ltd shares climbed over 2% to ₹299.30 in morning trade on Tuesday after the company announced it has received final approval from the US Food and Drug Administration (USFDA) for its Ab...
Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market
Mumbai-based Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market Rivaroxaban Tablets USP in stren...
Indoco Remedies signs Sale and Leaseback Agreemen for Waluj facility assets
Indoco Remedies Limited has announced a strategic move involving the sale and leaseback of some of its movable assets at its Waluj Facility in Aurangabad, Maharashtra. In a regulatory filing, the comp...
Indoco Remedies Transcript: Q1 25/26
Q1 FY26 saw sequential revenue and EBITDA improvement, driven by OTC and emerging markets, despite ongoing FDA remediation and flat domestic formulations. Debt reduction and cost control efforts continue, with all plants expected fully operational by Q3.
Indoco Remedies Q1 Results: Revenue flat at Rs 42 crore, Net loss of Rs 3.6 crore
Indoco Remedies Limited reported a net loss of Rs 3.64 crore for the quarter ended June 30, 2025 (Q1FY26), compared to a profit of Rs 1.82 crore in the corresponding quarter last year. This marks the ...
Indoco Remedies receives EU GMP certification for sterile drug facility in Goa
Indoco Remedies Ltd has received a Certificate of EU Good Manufacturing Practices (GMP) Compliance from the European Health Authorities for its sterile drug product manufacturing facility at Goa Plant...
Indoco Remedies launches Ticagrelor tablets in UK through subsidiary
Indoco Remedies Limited has officially launched its Ticagrelor film-coated tablets (90mg) in the United Kingdom through its subsidiary, Indoco Remedies UK Limited, on June 2, 2025. This marks a signif...
Indoco Remedies receives USFDA approval for Generic Allopurinol Tablets USP 200 mg
Indoco Remedies Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Allopurinol Tablets USP 200 mg. The ...
Indoco Remedies Transcript: Q4 24/25
Operational disruptions, regulatory setbacks, and heavy investments led to a challenging year with declining revenues and margins. Recovery is expected from Q2 as manufacturing normalizes, with strong domestic growth and OTC expansion anticipated.
Indoco Remedies shares drop 6% after US FDA issues Form 483 For Hyderabad CRO unit
Indoco Remedies’ stock fell 6% after its clinical research division, AnaCipher, received a Form 483 from the United States Food and Drug Administration (USFDA). As of 9:18 AM, the shares were trading ...
Indoco’s AnaCipher receives one Form 483 after USFDA inspection
Indoco Remedies Limited (Indoco) proudly announces that its Clinical Research Organisation, AnaCipher, has successfully completed a comprehensive 5-day inspection by the USFDA. The inspection took pla...
Indoco Remedies receives relief as GST department drops proceedings on Rs 15.51 crore tax claim
Indoco Remedies Limited announced that the Goods and Services Tax (GST) Authority has officially dropped proceedings related to a ₹15.51 crore tax claim against the company. The decision was issued by...
Indoco Remedies Transcript: Q3 24/25
Q3 FY25 saw a sharp revenue and margin decline due to supply disruptions in regulated markets, mainly from a US FDA warning letter and remediation activities. Domestic business remained strong, with key brands outperforming and new launches contributing to growth. Remediation costs and margin pressure are expected to persist for at least two more quarters.
Indoco Remedies Q3 FY25 Results: Revenue declines 6.2% YoY to Rs 410.55 crore; Net loss widens to Rs 28.40 crore
Indoco Remedies Limited released its financial results for the quarter ending December 31, 2024 (Q3 FY25), reporting a decline in revenue and a net loss due to increased expenses and operational chall...
Indoco Remedies shares plunge over 7% as Goa facility receives USFDA warning letter
Indoco Remedies’ shares fell sharply by 7.52% today following a significant setback, as the company’s Goa facility, contributing 65-70% of its revenue, received a warning letter from the USFDA. The wa...
Indoco Remedies receives USFDA warning letter for Goa facility
Indoco Remedies has received a warning letter from the USFDA for its Goa facility, following an inspection conducted from July 16-26, 2024. This follows the earlier notification on October 11, 2024, w...